Mark E. Einstein, MD, MS

Albert Einstein Cancer Center and Montefiore Medical Center

EinsteinDr. Mark Einstein is Director of Clinical Research for Women’s Health and Gynecologic Oncology for the Department of Obstetrics & Gynecology and Women’s Health at Albert Einstein College of Medicine’s Albert Einstein Cancer Center and Montefiore Medical Center in Bronx, New York.

Dr. Einstein’s primary research interests focus on the pathogenesis and therapy for cervical cancer. Specifically, he is studying the numerous pathways and targets involved in the malignant transformation of the cervix starting from the causative infectious agent- Human Papillomavirus (HPV). He has been very active in translating clinical trial and translational data into clinical practices regarding cervical cancer prevention including 1) member of the Steering Committee for the American Society for Colposcopy and Cervical Pathology (ASCCP) Cervical Screening and Management Guidelines, 2) Workgroup member and of the American Cancer Society and the Society of Gynecologic Oncologists separate recommendations for HPV vaccines as well as 3) a consultant to the World Health Organization (WHO), developing their modules on the immunologic basis of HPV vaccines, and harmonizing with current cervical cancer screening.

He Co-Chairs the Gynecologic Oncology Group (GOG) Immunotherapy subcommittee and a voting member of the GOG Cervix Committee. He is a member of the Board of Directors of the ASCCP, the premier guidelines organization for cervical cancer screening and treatment in the US and was a workgroup member for the recent cervical cancer guidelines update in 2012. Dr. Einstein chairs the Foundation for Women’s Cancer’s cervical cancer education efforts and serves on the Foundation’s Board of Directors. He is a Fellow of the American College of Obstetrics and Gynecology (ACOG), American College of Surgeons (ACS) and he is a peer-reviewer for numerous journals. He has received funding for cervical cancer-related translational research from the NIH, American Cancer Society, Gynecologic Cancer Foundation, ACOG and the Berlex Foundation.

Spotlight

Visit the Sisterhood of Survivorship page to read “Dena’s Story” — by a vulvar cancer survivor who has shared her story and wise words, and channeled her energy into her National Race to End Women’s Cancer team.

Awareness

Vaccine efficacy against vulvar infection with HPV 16/18 was comparable to the efficacy found against cervical infection 4 years after vaccination, according to researchers with the National Cancer Institute.

Research

The Foundation has published its 2014-2015 Research Grants and Awards Booklet with Applications. Please consider applying to become part of an elite group of physician-scientists committed to the well-being of women at risk for/affected by gyn malignancies.

Education

The next Ovarian Cancer Survivors Course will be Saturday, July 26, 2014 in Boston. For more information on courses, click here.